Accessibility Menu
Integra LifeSciences logo

Integra LifeSciences(NASDAQ) IART

Market Cap$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)+373%
5 Year-77%
1 Year+28%
1 Month-12%
$16.65
-15.74%
-3.11Today
Integra LifeSciences last closing stock price
MetricPriceDate
Last closeUSD 16.492026-07-29
Integra LifeSciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.38%USD 18.822026-07-22
1 month-12.01%USD 18.742026-06-29
3 month+56.45%USD 10.542026-04-30
Year to date+32.77%USD 12.422025-12-31
1 year+28.23%USD 12.862025-07-29
3 year-63.76%USD 45.502023-07-28
5 year-77.22%USD 72.392021-07-30
Since inception+372.68%USD 4.181995-08-16

Integra LifeSciences Financials at a Glance

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.65B

Net Income (TTM)

-$7.24M

EPS (TTM)

-$0.09

P/E Ratio

-2.55

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$16.65

Volume

5

Open

$18.50

Previous Close

$16.49

Daily Range

$16.04 - $19.00

52-Week Range

$8.70 - $20.49

Estimated Earnings Date

Oct 29, 2026

IART News

Foolcom-Featured.png

Integra (IART) Q2 Revenue Beats by 5%

Motley Fool Markets TeamJul 31, 2025
Surgery

Why Integra Lifesciences Stock Is Sinking Today

Keith SpeightsJul 29, 2024
Hand over eyes

Why Integra LifeSciences Stock Is Crashing Today

Keith SpeightsMay 23, 2023
operating room

Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today

Brian FeroldiJul 26, 2017
Surgical team - black and white photo

Integra LifeSciences' Stock Split: Why It Accomplished Nothing

Keith SpeightsApr 15, 2017

Integra Beats on the Bottom Line

Rich DupreyOct 29, 2013

A Solid Orthopedic Implants Manufacturer

Kanak KantiAug 22, 2013

Integra LifeSciences Holdings Beats Expectations But Takes A Step Back Anyway

Seth JaysonAug 1, 2013
Page 1

IART: Motley Fool Moneyball Superscore

36

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Integra LifeSciences

Integra makes medical tools that help doctors repair the human body. Its products treat patients with brain injuries, wounds, and ear conditions. These technologies help people recover more effectively after complex surgeries.

Tools for the Operating Room

  • Codman Specialty Surgical: Specialized tools used for brain surgery, pressure monitoring, and ear procedures; represents about 70% of revenue.
  • Tissue Technologies: Products used to help skin and human tissue regrow after burns or surgeries; generates about 30% of revenue.
  • Specialty Instrumentation: Comprehensive portfolio of reusable and disposable hand-held tools used in hospitals and clinics.
  • Private Label: Manufacturing of medical-grade collagen materials for other healthcare companies to use in their own products.

Moving the Business Forward

  • Acquired rights for the Durepair Dural Regeneration Matrix in 2024 to expand its brain surgery offerings.
  • Processes donated human tissue through its subsidiary BioD LLC to support wound reconstruction products.
  • Expanded its sales presence in Southeast Asia, India, South Korea, and Brazil during 2024 and 2025.
  • Began transferring manufacturing operations to a new, modern facility in Braintree, Massachusetts.

Where Integra Stands Out

Integra operates a global network serving hospitals and clinics across North America, Europe, and Asia. It specializes in regenerative technology, which uses natural and synthetic materials to help human tissue heal and grow back.

A Look at the Numbers

  • Revenue was $434.9 million in Q4 2025, down 1.7% from the previous year.
  • Operating income reached $556.2 million in Q4 2025, up 1461.2% year-over-year.
  • Net income fell to -$1.7 million in Q4 2025, a 108.8% drop that worsened from 2024.
  • Free cash flow hit -$37.2 million in Q4 2025, worsening 433% compared to the prior year.

The Evolution of Integra

Integra has transitioned from a specialized tissue firm into a global medical technology provider. Its focus on neurosurgery and wound care creates a diverse portfolio for modern surgical needs.

AI Generated • May 3, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

4,427

CEO

Stuart M. Essig, PhD, MBA

Website

www.integralife.com

Headquarters

Princeton, NJ 08540, US

IART Financials

Key Financial Metrics (TTM)

Gross Margin

40.40%

Operating Margin

39.81%

Net Income Margin

-0.44%

Return on Equity

-0.93%

Return on Capital

2.22%

Return on Assets

-0.70%

Earnings Yield

-39.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.80M

Volume

5

Avg. Volume

1.08M

Financials (TTM)

Gross Profit

$885.45M

Operating Income

$655.86M

EBITDA

$210.66M

Operating Cash Flow

$85.33M

Capital Expenditure

-$46.57M

Free Cash Flow

$38.76M

Cash & ST Invst.

$274.08M

Total Debt

$0.00

Integra LifeSciences Performance Analysis

Integra LifeSciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,557,666,0001.0%
20232023-12-31USD 1,541,573,000-1.0%
20242024-12-31USD 1,610,527,0004.5%
20252025-12-31USD 1,635,245,0001.5%
Integra LifeSciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.3%
Q42025-12-318.2%
Q12026-03-31-9.9%
Q22026-06-306.8%
Integra LifeSciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.169.3%
20232023-12-31USD 0.84-61.0%
20242024-12-31USD -0.09N/A
20252025-12-31USD -6.747368.1%
Integra LifeSciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3098.9%
Q42025-12-3168.5%
Q12026-03-31-170.3%
Q22026-06-30200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$418.76M

+0.8%

Gross Profit

$219.74M

+5.0%

Gross Margin

0.00%

N/A

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$289.78K

N/A

Employees

4,427

N/A

Net Income

$4.48M

+100.9%

EBITDA

$27.74M

+105.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$274.08M

+8.1%

Total Debt

$0.00

-100.0%

Accounts Receivable

$267.19M

-6.1%

Inventory

$492.01M

+5.8%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-0.70%

N/A

Return on Invested Capital

63.47%

N/A

Free Cash Flow

$37.65M

+435.4%

Operating Cash Flow

$22.80M

+155.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TNDMTandem Diabetes Care, Inc.
$18.59+4.67%
BCAXBicara Therapeutics Inc. Common Stock
$25.89-3.68%
SEPNSepterna Inc
$33.61-1.06%
EYPTEyePoint Pharmaceuticals, Inc.
$11.92-0.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About IART

What is the current price of Integra LifeSciences?

Integra LifeSciences is trading at $16.49 per share.

What is the 52-week range for Integra LifeSciences?

Over the past 52 weeks, Integra LifeSciences has traded between $8.70 and $20.49.

How much debt does Integra LifeSciences have?

As of the most recent reporting period, Integra LifeSciences reported total debt of $1.87B.

How much cash does Integra LifeSciences have on hand?

Integra LifeSciences reported $214.42M in cash and cash equivalents in its most recent financial results.

What is Integra LifeSciences’s dividend yield?

Integra LifeSciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services